Recombinant Anti-HOXA9 antibody [EPR3655(2)] (ab140631)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3655(2)] to HOXA9
- Suitable for: IP, WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-HOXA9 antibody [EPR3655(2)]
See all HOXA9 primary antibodies -
Description
Rabbit monoclonal [EPR3655(2)] to HOXA9 -
Host species
Rabbit -
Tested applications
Suitable for: IP, WBmore details
Unsuitable for: ChIP,Flow Cyt,ICC/IF or IHC-P -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human HOXA9 aa 250 to the C-terminus (C terminal). The exact sequence is proprietary.
-
Positive control
- WB: HepG2, Human thymus, U937, SW480 and 293T lysates; HepG2 cells. IP: Wild-type HEK-293 immunoprecipitated with anti-HOXA9 antibody ab140631.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, 59% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR3655(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab140631 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use a concentration of 10 µg/ml.
|
|
WB | (1) |
1/1000 - 1/10000. Predicted molecular weight: 30 kDa.
|
Notes |
---|
IP
Use a concentration of 10 µg/ml. |
WB
1/1000 - 1/10000. Predicted molecular weight: 30 kDa. |
Target
-
Function
Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. -
Involvement in disease
Note=A chromosomal aberration involving HOXA9 is found in a form of acute myeloid leukemia. Translocation t(7;11)(p15;p15) with NUP98.
Note=A chromosomal aberration involving HOXA9 may contribute to disease progression in chronic myeloid leukemia. Translocation t(7;17)(p15;q23) with MSI2. -
Sequence similarities
Belongs to the Abd-B homeobox family.
Contains 1 homeobox DNA-binding domain. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 3205 Human
- Omim: 142956 Human
- SwissProt: P31269 Human
- Unigene: 659350 Human
-
Form
HOXA9 is a transcription factor with a central role in both haemopoiesis and leukaemia. High levels of HOXA9 expression in haemopoietic cells is a characteristic feature of acute myeloid leukaemia (AML), and may be sufficient to cause this disease. Overexpression of Hoxa 9 markedly expands hematopoietic stem cells. -
Alternative names
- ABD-B antibody
- Abd-B, drosophila, homolog of antibody
- D6a9 antibody
see all
Images
-
Lane 1: Wild-type HEK-293 input
Lane 2: HOXA9 knockout HEK-293 input
Lane 3: Wild-type HEK-293 immunoprecipitated with anti-HOXA9 antibody ab140631
Lane 4: HOXA9 knockout HEK-293 immunoprecipitated with anti-HOXA9 antibody ab140631
Lane 5: Wild-type HEK-293 immunoprecipitated with isotype control antibody ab172730
Lane 6: HOXA9 knockout HEK-293 immunoprecipitated with isotype control antibody ab172730
HOXA9 was immunoprecipitated with Recombinant Anti-HOXA9 antibody [EPR3655(2)] (ab140631) at 10 µg ml-1. A non-specific band detected in the input material at 37 kDa was not immunoprecipitated. ab172730 was used as the isotype control. Western blot was performed on immunoprecipitates of wild-type and HOXA9 knockout HEK-293 cell lysates (ab273706).
To generate this image, wild-type and HOXA9 knockout HEK-293 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with VeriBlot for IP Detection Reagent (HRP) (ab131366) for 1 h at room temperature, washed again four times then imaged. -
All lanes : Anti-HOXA9 antibody [EPR3655(2)] (ab140631) at 1/1000 dilution
Lanes 1 & 5 : Wild-type HEK-293 nuclear cell lysate
Lanes 2 & 6 : Wild-type HEK-293 cytoplasmic cell lysate
Lanes 3 & 7 : HOXA9 knockout HEK-293 nuclear cell lysate
Lanes 4 & 8 : HOXA9 knockout HEK-293 cytoplasmic cell lysate
Lane 9 : HEK-293 Non-transfected control nuclear cell lysate
Lane 10 : HEK-293 Non-transfected control cytoplasmic cell lysate
Lane 11 : HEK-293 scrambled siRNA transfected nuclear cell lysate
Lane 12 : HEK-293 scrambled siRNA transfected cytoplasmic cell lysate
Lane 13 : HEK-293 HOXA9 siRNA transfected nuclear cell lysate
Lane 14 : HEK-293 HOXA9 siRNA transfected cytoplasmic cell lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 30 kDa
Observed band size: 35 kDa why is the actual band size different from the predicted?False colour image of Western blot: Anti-HOXA9 antibody [EPR3655(2)] staining at 1/1000 dilution, shown in green; Mouse anti-Alpha Tubulin [DM1A] (ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab140631 was shown to bind specifically to HOXA9. A band was observed at 35 kDa in wild-type HEK-293 cell lysates with no signal observed at this size in HOXA9 knockout cell line. The HOXA9 band is at approximately 35 kDa. This band is present in the nuclear fraction and is absent in the KO. The identity of the brighter band at 37 kDa is unknown but is non-specific as it is present in all samples. To generate this image, wild-type and HOXA9 knockout HEK-293 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
Datasheets and documents
-
SDS download
-
Datasheet download
References (20)
ab140631 has been referenced in 20 publications.
- Fiskus W et al. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12:5 (2022). PubMed: 35017466
- Liu J et al. Long non-coding RNA PCED1B-AS1 promotes the proliferation of colorectal adenocarcinoma through regulating the miR-633/HOXA9 axis. Bioengineered 13:5407-5420 (2022). PubMed: 35176937
- Li ZL et al. MiR-19b-3p promotes tumor progression of non-small cell lung cancer via downregulating HOXA9 and predicts poor prognosis in patients. Histol Histopathol 37:779-789 (2022). PubMed: 35274735
- Zhang S & Chen R LINC01140 regulates osteosarcoma proliferation and invasion by targeting the miR-139-5p/HOXA9 axis. Biochem Biophys Rep 31:101301 (2022). PubMed: 35800618
- Sahoo BK et al. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia. Haematologica N/A:N/A (2022). PubMed: 36005562